Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 1, 2015, Pages 75-85

  Calip, Gregory S ^a,b   Hubbard, Rebecca A ^a,c   Stergachis, Andy ^a   Malone, Kathleen E ^a,b   Gralow, Julie R ^d   Boudreau, Denise M ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Breast cancer; Diabetes mellitus; Glycemic control; Medication adherence; Pharmacoepidemiology

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PRIORITY JOURNAL; VERY ELDERLY; ADOLESCENT; BLOOD; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; TIME FACTOR; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BREAST NEOPLASMS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84920999032     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3660     Document Type: Article

References (48)

1. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. American Cancer Society, Inc: Atlanta, 2013.
2. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-294.
3. Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Prac Am Soc Clin Oncol 2011; 7: 371-374.
4. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118(Suppl 5A): 27S-34S.
5. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res 2013; 11: 54-65.
6. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006; 12: 466-471.
7. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004; 10: 144-151.
8. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004; 27: 2149-2153.
9. Peyrot M, McMurry JF, Jr., Kruger DF. A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav 1999; 40: 141-158.
10. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862.
11. Liao S, Li J, Wei W, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 2011; 12: 1061-1065.
12. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012; 107: 1608-1617.
13. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.
14. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-2764.
15. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007; 120: 1986-1992.
16. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 2013; 24: 2506-2514.
17. Li CI, Daling JR, Tang MT, Malone KE. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 2011; 125: 545-551.
18. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-1123.
19. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685.
20. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813-822.
21. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012; 30: 2844-2852.
22. Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Prac Am Soc Clin Oncol 2012; 8: e149-e157.
23. Wirtz HS, Buist DS, Gralow JR, et al. Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev 2013; 22: 1588-1599.
24. Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 2014; 144: 405-416.
25. Group Health Breast Cancer Surveillance Registry. http://www.grouphealthresearch.org/surveillanceproject/. Accessed June 15, 2011.
26. Saunders KW, Davis RL, Stergachis A. Group health cooperative. In Pharmacoepidemiology, Strom BL (ed.). J. Wiley: Chichester; Hoboken, NJ, 2005; 223-239.
27. Washington State Department of Health, Center for Health Statistics. Death data. http://www.doh.wa.gov/ehsphl/CHS/chs-data/death/deatmain.htm. Accessed June 15, 2011.
28. Bryson CL, Au DH, Young B, McDonell MB, Fihn SD. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care 2007; 45: 497-504.
29. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574; discussion 575-567.
30. American Diabetes A. Standards of medical care in diabetes. Diabetes Care 2013; 36(Suppl 1): S11-S66.
31. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J 1995; 310: 170.
32. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
33. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2: 48-53.
34. Hewitt ME, Ganz PA, Institute of Medicine (U.S.). American Society of Clinical Oncology (U.S.). From cancer patient to cancer survivor: lost in transition: an American Society of Clinical Oncology and Institute of Medicine Symposium. National Academies Press: Washington, D.C, 2006.
35. Snyder CF, Frick KD, Kantsiper ME, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009; 27: 1054-1061.
36. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167.
37. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003; 157: 1092-1100.
38. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013; 36: 3018-3026.
39. Peeters PJ, Bazelier MT, Vestergaard P, et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013; 8: 357-363.
40. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014. doi: 10.1111/dom.12267.
41. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010; 16: 1695-1700.
42. Buist DS, LaCroix AZ, Brenneman SK, Abbott T, 3rd. A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 2004; 52: 1130-1137.
43. Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG. Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 2004; 38: 1317-1318.
44. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; CD000011.
45. Weiss NS. Estimating the impact of the discontinuation of medical interventions on health outcomes. Am J Epidemiol 2009; 169: 653-656.
46. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.
47. Wagner EH, Grothaus LC, Sandhu N, et al. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. Diabetes Care 2001; 24: 695-700.
48. McCulloch DK, Price MJ, Hindmarsh M, Wagner EH. A population-based approach to diabetes management in a primary care setting: early results and lessons learned. Eff Clin Pract 1998; 1: 12-22.